Download QT Vascular`s Products Receive Positive Feedback at World`s

80 Robinson Road #02-00 Singapore 068898
Tel: +65 6438 2990 Fax: +65 66438 0064 Web: www.qtvascular.com
FOR IMMEDIATE RELEASE
QT Vascular’s Products Receive Positive Feedback at
World’s Largest Interventional Cardiovascular
Conference
•
TCT (Transcatheter Cardiovascular Therapeutics) is the world’s largest
educational meeting specializing in interventional cardiovascular medicine
•
Recognition of unique potential of products by eminent group of world-renowned
physicians is expected to further increase awareness among physicians
•
Growth strategy of rapidly and concurrently advancing pipeline products via both
organic (in-house) and inorganic (licensing and acquisition) efforts
Singapore, 23 September 2014 – Catalist-listed QT Vascular Ltd. (“QT Vascular” or together with its
subsidiaries, “the Group”), a developer and manufacturer of minimally invasive medical devices for the
treatment of vascular diseases, is pleased to announce that it has concluded a successful presence at
the TCT conference in Washington DC, that included several scientific presentations and the use of one
of its products during a live case transmission.
Specifically, these presentations and live-case transmissions included the following:
•
In a live satellite transmission from Riverside Methodist Hospital in Columbus Ohio, to the convention
center in Washington DC, Dr. Gary Ansel used a 3.0x80mm Chocolate
®
PTA to treat a patient
suffering from severely stenosed popliteal artery. Due to its location behind the knee which is subject
to extreme bending and compression, the popliteal artery is sometimes considered a “no-stent” zone.
•
®
TriReme’s Chocolate
PTA technology was prominently featured in several presentations at the
“New Paradigms for Coronary and Peripheral Interventions Symposium” on September 14th 2014:
o
In a presentation titled “Introduction: Beyond Balloons and Stents”, Dr. Martin Leon,
Professor of Medicine at Columbia University Medical Center described the history of
interventional tools from balloons to stents. Despite the progress made in reducing restenosis
by the use of drug-eluting stents, concerns are mounting due to the increasing cumulative
incidence of late thrombosis. This has opened the door for treatment platforms that do not
leave behind a permanent implant.
o
Dr. Jihad Mustapha, Director of Endovascular lab and Cardiovascular research at Metro
hospital in Grand Rapids Michigan, presented updated interim results of the Chocolate BAR
registry. The Chocolate® BAR registry has now enrolled a total of over 480 patients (one of
the largest peripheral registries), including over 220 patients in the highly complex below-theknee (BTK) cohort. Remarkably, only 2% of the patients in this challenging cohort required a
bail out stent and at 3 months, the rate of amputation-free survival was a high 98%, while the
rate of re-intervention was only 5%.
o
Dr. Mehdi Shishehbor, Director of Endovascular Services at the Cleveland Clinic discussed
the limitations of current endovascular treatment options, the shift away from the use of
®
permanent implants, and the role that Chocolate PTA plays in his treatment of high risk
Page 1 of 3
80 Robinson Road #02-00 Singapore 068898
Tel: +65 6438 2990 Fax: +65 66438 0064 Web: www.qtvascular.com
patients such as those with critical limb ischemia. He closed by announcing the trial structure
of ENDURE, a clinical trial of the Group’s drug coated balloon, Chocolate® Touch.
o
®
In a presentation titled “Chocolate PTCA – A New Treatment Paradigm and Case Review”,
Dr. Bruno Scheller of University of Saarland, Germany, described the initial experience in
®
using the Chocolate PTCA (heart version) as a vessel preparation device prior to the use of
a drug-coated balloon or a drug-eluting stent in coronary de novo lesions. In this early
experience with the device, coronary stents were used in less than 60% of lesions (compared
to over 90% in everyday practice for his heart patients).
o
Dr. David Rizik, Director of the Heart and Vascular Division of the Scottsdale (AZ) Heart
Group presented the results of the Glider PTCA EU registry, showed several successful case
studies demonstrating Glider’s specialty characteristics in treating lesions that are difficult and
sometimes impossible to treat with conventional balloons, and announced the plans for a
clinical registry of Glider use in the United States.
Dr. Eitan Konstantino, the Group’s Chief Executive Officer, commented, “It is an honour that such
an eminent group of world-renowned physicians has recognized the unique potential of our
peripheral and coronary products. We will continue to invest in development of cutting edge
technologies and will also look to license and or acquire unique products that offer improved
treatment options for patients and could expand our line of specialty balloons and catheters.”
- End –
About Coronary Artery Disease
Coronary artery disease occurs when the coronary arteries (the arteries surrounding the heart) become narrowed by
a buildup of plaque, including cholesterol, fatty deposits, calcium, and other substances. As plaque accumulates over
time, the diameter of the arterial lumen, or inner channel, narrows, resulting in reduced or stopped blood flow. When
this occurs in arteries supplying blood to the heart, it can cause chest pain, a heart attack, or even death.
About Peripheral Artery Disease
Peripheral artery disease (PAD) is caused by the build-up of fatty substances that collect and adhere to the linings of
the arteries, in a process known as atherosclerosis. The build-up causes the internal lining of the artery to thicken,
narrowing the artery and limiting blood flow to vital tissues and organs. Commonly affected arteries include those
located in the legs, arms, neck and kidneys. The vast majority of patients with PAD also have significant concomitant
coronary artery disease (CAD) and a high proportion of morbidity and mortality in these patients is related to
myocardial infarction, ischemic stroke or cardiovascular death. PAD is estimated to affect 202 million people
worldwide.
About QT Vascular Ltd.
QT Vascular Ltd. (QT Vascular) is an emerging leader in the development and commercialization of next generation
minimally invasive products for the treatment of complex vascular disease. The Company works closely with leading
physicians and scientists from around the world to create differentiated devices that improve procedural and clinical
outcomes. QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC, in Pleasanton, California.
The Company was listed on the Catalist Board of the Singapore Exchange Securities Trading Limited on 29 April
2014.
For more information, please refer to: http://www.qtvascular.com/
References:
(1)
Das T for Mustapha J. Chocolate® Bar, Leipzig Interventional Course, 28-31 January, 2014.
(2)
"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a
systematic review and analysis." 19 Oct 2013. The Lancet.
Page 2 of 3
80 Robinson Road #02-00 Singapore 068898
Tel: +65 6438 2990 Fax: +65 66438 0064 Web: www.qtvascular.com
Issued for and on behalf of QT Vascular Ltd.
by Financial PR Pte Ltd
Kamal SAMUEL, [email protected]
Mark LIN, [email protected]
Tel: (65) 6438 2990 Fax: (65) 6438 0064
Cautionary Note on Forward-Looking Statements
All statements other than statements of historical facts included in this announcement are or may be
forward-looking statements. Forward-looking statements include but are not limited to those using
words such as “expect”, “anticipate”, “believe”, “estimate”, “intend”, “project”, “plan”, “strategy”,
“forecast” and similar expressions or future or conditional verbs such as “if”, “will”, “would”, “should”,
“could”, “may” and “might”. These statements reflect the Company’s current expectations, beliefs, hopes,
intentions or strategies regarding the future and assumptions in light of currently available information.
Such forward-looking statements are not guarantees of future performance or events and involve known
and unknown risks and uncertainties. Accordingly, actual results may differ materially from those
described in such forward-looking statements. Shareholders should not place undue reliance on such
forward-looking statements, and the Company undertakes any obligation to update publicly or revise
any forward-looking statements, subject to compliance with all applicable laws and regulations and/or
the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.
The Company was listed on Catalist board of the Singapore Exchange Securities Trading Limited (the
"SGX-ST") on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners
Corporate Finance Pte. Ltd. (the "Sponsor").
This press release has been prepared by the Company and its contents have been reviewed by the
Sponsor for compliance with the relevant rules of the SGX-ST. The Sponsor has not independently verified
the contents of this press release.
This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no
responsibility for the contents of this press release including the correctness of any of the statements or
opinions made or reports contained in this press release.
The contact person for the Sponsor is Mr Mark Liew, Managing Director, Corporate Finance, at 20 Cecil
Street, #21-02 Equity Plaza, Singapore 049705, telephone +65 6229 8088.
Page 3 of 3